search
Back to results

The Effects of tDCS on the Neuronal Mechanisms of Cognitive Control in Schizophrenia

Primary Purpose

Schizophrenia

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Transcranial Direct Current Stimulation
Sponsored by
University of California, Davis
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Schizophrenia focused on measuring Schizophrenia, Transcranial Direct Current Stimulation, tDCS, Cognitive Control, fMRI, Dorsolateral Prefrontal Cortex

Eligibility Criteria

18 Years - 35 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria

  • Sufficient English literacy so as to be able to understand and complete cognitive tasks.
  • The ability to give valid informed consent.
  • Diagnosis of schizophrenia, schizophreniform or schizoaffective disorder (for patient group)
  • Stable outpatient or partial hospital status (for patient group)

Exclusion Criteria

  • Psychiatric medication changes in the prior month (for patient group)
  • No psychiatric medication changes anticipated in the upcoming month (for patient group)
  • Intelligence Quotient (IQ) < 70; IQ will be measured by administering the Wechsler Abbreviated Scale of Intelligence (WASI) test.
  • People under the age of 18
  • Pregnant Women
  • Prisoners
  • Pacemakers
  • Implanted brain stimulators
  • Implanted defibrillator
  • Metallic implants
  • Skin damage or skin conditions such as eczema at the sites where electrodes will be placed
  • Dreadlocks or other hair styles hindering the placement of tDCS electrodes
  • Cranial pathologies
  • Head trauma
  • Epilepsy
  • Mental retardation
  • Neurological disorders
  • Uncorrected vision problems that would hinder cognitive testing (this also pertains to subjects with color blindness in tasks where discriminating colored objects/items is necessary for successful performance).
  • Other than nicotine, no subjects reporting substance dependence in the past six months and no substance abuse in the past month

Sites / Locations

  • Imaging Research Center, University of California Davis Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Experimental Stimulation

Sham Stimulation

Arm Description

Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex

Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation

Outcomes

Primary Outcome Measures

Dorsolateral Prefrontal Cortex Response
Blood oxygen level-dependent response of the dorsolateral prefrontal cortex during a cognitive control task (Dot-Probe Expectancy Task)
Behavioral Response
Cognitive control-related performance (d-prime context) associated with the task (Dot-Probe Expectancy Task)

Secondary Outcome Measures

Full Information

First Posted
March 1, 2017
Last Updated
October 9, 2023
Sponsor
University of California, Davis
search

1. Study Identification

Unique Protocol Identification Number
NCT03077347
Brief Title
The Effects of tDCS on the Neuronal Mechanisms of Cognitive Control in Schizophrenia
Official Title
The Effects of Transcranial Direct Current Stimulation on the Neuronal Mechanisms of Cognitive Control in Schizophrenia
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Terminated
Why Stopped
Stimulation did not show any evidence of the anticipated effect after 6 participants completed the study. Study was thus halted.
Study Start Date
April 1, 2017 (Actual)
Primary Completion Date
February 23, 2023 (Actual)
Study Completion Date
February 23, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, Davis

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to better understand the neural correlates of cognitive control (CC) deficits in schizophrenia and determine how these mechanisms can be modulated by transcranial direct current stimulation (tDCS). CC is a critical neurocognitive process that is required for flexible, directed thought and action based on goals and intentions. Identifying and developing paradigms to improve CC is therefore a mental health priority. Current theories of CC postulate that recruitment of the dorsolateral prefrontal cortex (DLPFC) is essential for this process by maintaining high-level information that it can then use to orchestrate patterns of activation in other brain networks to support optimal performance. tDCS is a safe, noninvasive method of modulating regional brain excitability via brief (15-20 m) application of a weak (1-2 mA) current. The goal of the proposed experiments is to combine tDCS with functional magnetic resonance imaging (fMRI) to test the hypotheses that 1) acute tDCS over the DLPFC can improve performance during a CC task (the dot pattern expectancy (DPX) variant of the AX-Continuous Performance Task) in schizophrenia patients and healthy control subjects, and 2) acute tDCS over the DLPFC can increase recruitment of the DLPFC during the DPX. Effects of tDCS on brain functional connectivity (during CC as well as during the resting state) will also be examined, as well as effects on an episodic memory task. The current study will be the first to use functional magnetic resonance imaging (fMRI) to examine the effects of tDCS on the neuronal mechanisms of CC in schizophrenia, and has potentially important implications for therapeutic development for this treatment refractory yet disabling aspect of the illness.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia
Keywords
Schizophrenia, Transcranial Direct Current Stimulation, tDCS, Cognitive Control, fMRI, Dorsolateral Prefrontal Cortex

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Sham Stimulation followed by Direct Current Stimulation or Vice-Versa
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
6 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Experimental Stimulation
Arm Type
Experimental
Arm Description
Intervention. 20 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex
Arm Title
Sham Stimulation
Arm Type
Placebo Comparator
Arm Description
Placebo Comparator. 0.5-1 minutes of 2 mA direct current stimulation over the dorsolateral prefrontal cortex followed by 19-19.5 minutes of sham stimulation
Intervention Type
Device
Intervention Name(s)
Transcranial Direct Current Stimulation
Other Intervention Name(s)
tDCS
Intervention Description
In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
Primary Outcome Measure Information:
Title
Dorsolateral Prefrontal Cortex Response
Description
Blood oxygen level-dependent response of the dorsolateral prefrontal cortex during a cognitive control task (Dot-Probe Expectancy Task)
Time Frame
Assessment will begin immediately following stimulation and last for up to an hour.
Title
Behavioral Response
Description
Cognitive control-related performance (d-prime context) associated with the task (Dot-Probe Expectancy Task)
Time Frame
Assessment will begin immediately following stimulation and last for up to an hour.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria Sufficient English literacy so as to be able to understand and complete cognitive tasks. The ability to give valid informed consent. Diagnosis of schizophrenia, schizophreniform or schizoaffective disorder (for patient group) Stable outpatient or partial hospital status (for patient group) Exclusion Criteria Psychiatric medication changes in the prior month (for patient group) No psychiatric medication changes anticipated in the upcoming month (for patient group) Intelligence Quotient (IQ) < 70; IQ will be measured by administering the Wechsler Abbreviated Scale of Intelligence (WASI) test. People under the age of 18 Pregnant Women Prisoners Pacemakers Implanted brain stimulators Implanted defibrillator Metallic implants Skin damage or skin conditions such as eczema at the sites where electrodes will be placed Dreadlocks or other hair styles hindering the placement of tDCS electrodes Cranial pathologies Head trauma Epilepsy Mental retardation Neurological disorders Uncorrected vision problems that would hinder cognitive testing (this also pertains to subjects with color blindness in tasks where discriminating colored objects/items is necessary for successful performance). Other than nicotine, no subjects reporting substance dependence in the past six months and no substance abuse in the past month
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Cameron Carter, M.D.
Organizational Affiliation
University of California, Davis
Official's Role
Study Director
Facility Information:
Facility Name
Imaging Research Center, University of California Davis Medical Center
City
Sacramento
State/Province
California
ZIP/Postal Code
95817
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Select data from this study may be submitted to the National Institute of Mental Health Data Archive (NDA). NDA is a data repository run by the National Institute of Mental Health (NIMH) that allows researchers studying mental illness to collect and share de-identified information with each other. The data repository is accessible only to qualified investigators. All subject data will be de-identified (subject names will not be used) and each subject will have a separate identifier called a Global Unique Identifier (GUID) to remove any possibility that "the identities of the subjects cannot be readily ascertained or otherwise associated with the data by the repository staff or secondary data users" (45 Code of Federal Regulations, 46.102).

Learn more about this trial

The Effects of tDCS on the Neuronal Mechanisms of Cognitive Control in Schizophrenia

We'll reach out to this number within 24 hrs